GET DAILY SIGNALSWhy Is Harmony Biosciences Holdings (HRMY) Stock Down -10.35% Today?
Key Takeaways
- HRMY shares fell about 10.35% in Wednesday's session after a third-quarter earnings and revenue miss.
- The primary catalyst was weaker-than-expected Q3 2026 results: EPS of $0.81 versus consensus near $1.09–$1.11, and revenue of $268.9 million versus estimates around $272 million.
- Higher cost of goods sold and a $25 million milestone charge weighed on profitability, while the company only reiterated its full-year WAKIX revenue guidance of $1.00 billion–$1.04 billion.
- The move was largely company-specific, with the stock diverging from broader equity indices and sector peers during the session.
- Traders are now watching management commentary, WAKIX prescription trends, and pipeline updates for the next catalyst.
- For deeper analysis, explore Price Targets, Earnings, and Forecast pages for HRMY.
- Discover which AI trading strategies are outperforming in the current market by exploring Trending AI Robots.
Opening Summary
HRMY — Harmony Biosciences Holdings, Inc. — is a commercial-stage biopharmaceutical company focused on therapies for rare neurological diseases, anchored by its lead product WAKIX (pitolisant) for excessive daytime sleepiness in narcolepsy. The stock dropped roughly 10.35% on Wednesday, trading near $33.19 intraday, down from the prior session's close of $37.02. The decline was driven by a third-quarter earnings report that missed Wall Street expectations on both the top and bottom lines, overshadowing the company's reaffirmed full-year guidance and positive early-stage pipeline data.
Earnings Miss Weighs on the Stock
The dominant catalyst for the decline was the company's third-quarter 2026 financial results, released before the market opened. HRMY reported adjusted earnings of $0.81 per share, well below consensus estimates that ranged from roughly $1.09 to $1.11. Revenue of $268.9 million also came in short of analyst projections near $272 million, despite continued demand growth in the WAKIX franchise.
The earnings shortfall reflected higher cost of goods sold and a $25 million milestone charge related to the pipeline, which compressed profitability even as underlying product demand held up. For a company whose investment thesis rests heavily on the durability of WAKIX and margin expansion, the profit miss gave investors a concrete reason to reassess near-term valuation.
Guidance Reiteration and Mixed Signals
Compounding the earnings disappointment, management reiterated rather than raised its full-year 2026 WAKIX revenue outlook of $1.00 billion to $1.04 billion. While consistent guidance is often viewed as stability, in the context of a quarterly profit miss, the lack of an upward revision left little to offset investor concerns. Meanwhile, positive data from the company's BP-205 program and the announced transition to a new CEO, Peter Anastasiou, effective January 1, 2027, were not enough to counterbalance the headline miss.
Market Context and Trading Activity
The selloff in HRMY was largely stock-specific, driven by the earnings report rather than a broad rotation out of the healthcare sector. While broader equity indices held relatively steady, the stock broke decisively below its prior session's trading range, breaching near-term support and surrendering recent gains. The move pushed the shares toward the lower end of their recent range, well off their 52-week high, and elevated trading activity reflected the post-earnings repricing. Peers in the specialty and rare-disease pharmaceutical space did not move in tandem, underscoring that this was an earnings-driven move unique to the company.
What Comes Next for HRMY
Looking ahead, investors will focus on several factors. Management's commentary on WAKIX prescription trends and net patient additions will be closely scrutinized, as will the execution of the company's broader pitolisant and rare-disease pipeline programs. The planned CEO transition introduces a layer of execution and strategic uncertainty that markets will monitor into early 2027. Additionally, ongoing patent-related considerations for the WAKIX franchise remain a key risk to the long-term outlook. Upcoming data readouts and quarterly results will be pivotal in determining whether the stock can reclaim the levels lost in Wednesday's session.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots that are currently demonstrating the strongest performance. Tickeron offers hundreds of these bots covering thousands of tickers, each varying by strategy, timeframe, performance metrics, and the symbols they trade. Because only the best performers under current market conditions are featured, the page offers a useful way to explore quantitative approaches to navigating volatile, news-driven moves like the one seen in HRMY. Consider exploring the Trending AI Robots to see which strategies are leading today's market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
HRMY's RSI Indicator ascending out of oversold territory
The RSI Oscillator for HRMY moved out of oversold territory on October 14, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 31 similar instances when the indicator left oversold territory. In 27 of the 31 cases the stock moved higher. This puts the odds of a move higher at 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for HRMY just turned positive on October 28, 2026. Looking at past instances where HRMY's MACD turned positive, the stock continued to rise in 31 of 40 cases over the following month. The odds of a continued upward trend are 77%.
Following a +0.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where HRMY advanced for three days, in 206 of 282 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
HRMY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 49 of 60 cases where HRMY's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 82%.
The Momentum Indicator moved below the 0 level on November 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HRMY as a result. In 73 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
HRMY moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for HRMY crossed bearishly below the 50-day moving average on October 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HRMY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
The Aroon Indicator for HRMY entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 22 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 46 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating steady price growth. HRMY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 80 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.158) is normal, around the industry mean (3.051). P/E Ratio (11.827) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (2.581) is also within normal values, averaging (439.647).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HRMY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a commercial-stage pharmaceutical company, which engages in the development and commercialization of therapies for the treatment of neurological disorders
Industry Biotechnology
Advertisement